Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983857 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL31432721 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL1768918 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL3182833 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL22721397 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL1341976 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL6666152 | 0.98 | FABP3 (0.52) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL617162 | 0.92 | ALDH1A1 (0.53) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL1643923 | 0.87 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL5475892 | 0.87 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844109-B2 | Method for producing erythrocyte proteins | INSTITUT NATIONAL TRANSFUSION SANGUINE (FR) | 2020-11-24 | — | — | US | claimed |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-04-11 | — | — | US | claimed |
| EP-4642434-A2 | LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4565572-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4547282-A1 | LIPID COMPOSITIONS FOR IN VIVO DELIVERY | Life Technologies Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250092143-A1 | GENETICALLY ENGINEERED MULTIFUNCTIONAL EXOSOMES FOR IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2025047645-A1 | METHOD FOR SIMULTANEOUS DETECTION OF BIOMOLECULES USING TEMPERATURE-RESPONSIVE FLUORESCENT PARTICLES | 学校法人早稲田大学 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024182731-A1 | INJECTABLE COMPOSITIONS OF VITAMERS OF VITAMIN B12 AND USES THEREOF | NEVAKAR INJECTABLES INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240263196-A1 | Lipid Compositions and Methods for Delivery to Immune Cells | Life Technologies Corporation | 2024-08-08 | — | — | US | disclosed |
| US-12040170-B2 | Methods and apparatuses for deconvolution of mass spectrometry data | PROTEIN METRICS, LLC (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-1994147-A1 | USE OF A THERMOSTABLE PHOSPHOLIPASE IN THE DEGUMMING OF AN OIL OR FAT, AND A METHOD FOR OBTAINING A THERMOSTABLE PHOSPHOLIPASE | Sued-Chemie AG (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2007059927-A1 | USE OF A THERMOSTABLE PHOSPHOLIPASE IN THE DEGUMMING OF AN OIL OR FAT, AND A METHOD FOR OBTAINING A THERMOSTABLE PHOSPHOLIPASE | Süd-Chemie AG (DE) | 2007-05-31 | — | — | WO | disclosed |
| EP-1161688-B1 | COLORIMETRIC DETECTION METHOD | UNIV BEN GURION (IL) | 2007-02-28 | — | — | EP | disclosed |
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-03-30 | — | — | US | disclosed |
| WO-2004080396-A2 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (US) | 2004-09-23 | — | — | WO | disclosed |
| EP-1161688-A2 | COLORIMETRIC DETECTION METHOD | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000055623-A2 | COLORIMETRIC DETECTION METHOD | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | PNLIP, SGMS2, SGMS1 | FABP3 430/4885SMN1; SMN2 1122/4885NR5A2 3636/4885 |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | PNLIP, BRCA1, IAPP | FABP3 320/4885SMN1; SMN2 571/4885NR5A2 2329/4885 |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | LCAT, SGMS2, SGMS1 | FABP3 572/4885SMN1; SMN2 2690/4885NR5A2 3393/4885 |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | MEN1, VHL, CALM1 | FABP3 845/4885SMN1; SMN2 354/4885NR5A2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.